Skip to main content

Advertisement

SpringerLink
Log in

Infectious Prophylaxis in Paediatric Oncology and Stem Cell Transplantation

  • Hematology/Oncology (C Cole, Section Editor)
  • Published:
Current Pediatrics Reports Aims and scope Submit manuscript

Abstract

The advances in the survival of children with cancer and following stem cell transplant have, in part, been due to more effective infection prevention strategies. Morbidity and mortality following bacterial, viral and fungal infection remain significant necessitating further refinement of existing prophylactic strategies. Novel antiviral agents, newer and better tolerated antifungal drugs, antibiotic bacterial prophylaxis and adoptive immunotherapy in high-risk groups are potential approaches for which supportive evidence is emerging. Questions remain as to the optimal approach to infectious prophylaxis using currently available agents. There is a clear need for further directed paediatric research in this area.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;110(10):3532–9.

    Article  CAS  PubMed  Google Scholar 

  2. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45(10):1296–304.

    Article  PubMed  Google Scholar 

  3. • Alexander S, Nieder M, Zerr DM, Fisher BT, Dvorak CC, Sung L. Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn? Pediatr Blood Cancer. 2012; 59(1): 16–20. Summary of current paediatric data in bacterial prophylaxis and directions for future research.

  4. Johannsen KH, Handrup MM, Lausen B, Schroder H, Hasle H. High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine. Pediatr Blood Cancer. 2013;60(7):1154–60.

    Article  CAS  PubMed  Google Scholar 

  5. Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European bone marrow transplantation survey. Br J Haematol. 2002;117(2):444–50.

    Article  PubMed  Google Scholar 

  6. de Blank P, Zaoutis T, Fisher B, Troxel A, Kim J, Aplenc R. Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr. 2013;163(3):699–705 e1.

    Article  PubMed  Google Scholar 

  7. •• Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012; 1: CD004386. A meta-analysis of available adult RCTs comparing antibiotic prophylaxis with placebo/no treatment. Demonstrating a reduction in all cause mortality and infection-related death. Prophylaxis was associated with more frequent medication side effects and increased antibiotic resistance.

  8. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):427–31.

    Article  PubMed  Google Scholar 

  9. Castagnola E, Boni L, Giacchino M, et al. A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J. 2003;22(4):359–65.

    PubMed  Google Scholar 

  10. Schroder H, Agger KE, Rosthoj S, Carlsen NT, Schmiegelow K. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia. Dan Med Bull. 2001;48(4):275–7.

    CAS  PubMed  Google Scholar 

  11. • Laoprasopwattana K, Khwanna T, Suwankeeree P, Sujjanunt T, Tunyapanit W, Chelae S. Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy. Pediatr Infect Dis J. 2013; 32(3): e94–8. Paediatric RCT of 95 patients demonstrating a significant reduction in febrile episodes in neutropenic patients given ciprofloxacin prophylaxis compared with placebo. Resistance to ciprofloxacin in bacterial isolates was increased in the prophylaxis group. Few paediatric RCTs are available.

  12. Inaba H, Gaur AH, Cao X, et al. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer. 2014;120(13):1985–92.

    Article  CAS  PubMed  Google Scholar 

  13. Lehrnbecher T, Ethier MC, Zaoutis T, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukemia. Br J Haematol. 2009;147(1):125–8.

    Article  PubMed  Google Scholar 

  14. Engelhard D, Akova M, Boeckh MJ, et al. Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):467–70.

    Article  CAS  PubMed  Google Scholar 

  15. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009;43(10):757–70.

    Article  CAS  PubMed  Google Scholar 

  16. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev. 2009;1:Cd006706.

    PubMed  Google Scholar 

  17. Blennow O, Fjaertoft G, Winiarski J, Ljungman P, Mattsson J, Remberger M. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis—the incidence remains high. Biol Blood Marrow Transplant. 2014;20(10):1646–9.

    Article  PubMed  Google Scholar 

  18. Vermont CL, Jol-van der Zijde EC, Hissink Muller P, et al. Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity. Transpl Infect Dis. 2014;16(2):188–94.

    Article  CAS  PubMed  Google Scholar 

  19. Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis. 2008;197(Suppl 2):S165–9.

    Article  PubMed  Google Scholar 

  20. Hardy I, Gershon AA, Steinberg SP, LaRussa P, Varicella Vaccine Collaborative Study Group. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N Engl J Med. 1991;325(22):1545–50.

    Article  CAS  PubMed  Google Scholar 

  21. Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014;342(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  22. Rasche L, Kapp M, Einsele H, Mielke S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant. 2014;49(2):163–7.

    Article  CAS  PubMed  Google Scholar 

  23. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Uhlin M, Wikell H, Sundin M, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99(2):346–52.

    Article  PubMed Central  PubMed  Google Scholar 

  25. George D, El-Mallawany NK, Jin Z, et al. Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortality. Br J Haematol. 2012;156(1):99–108.

    Article  PubMed  Google Scholar 

  26. Mynarek M, Ganzenmueller T, Mueller-Heine A, et al. Patient, virus, and treatment-related risk factors in pediatric adenovirus infection after stem cell transplantation: results of a routine monitoring program. Biol Blood Marrow Transplant. 2014;20(2):250–6.

    Article  PubMed  Google Scholar 

  27. Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood. 2010;116(25):5476–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14(6):555–63.

    Article  CAS  PubMed  Google Scholar 

  29. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;59(Suppl 5):S344–51.

    Article  PubMed  Google Scholar 

  30. Kersun LS, Coffin SE, Leckerman KH, Ingram M, Reilly AF. Community acquired influenza requiring hospitalization: vaccine status is unrelated to morbidity in children with cancer. Pediatr Blood Cancer. 2010;54(1):79–82.

    Article  PubMed  Google Scholar 

  31. Tasian SK, Park JR, Martin ET, Englund JA. Influenza-associated morbidity in children with cancer. Pediatr Blood Cancer. 2008;50(5):983–7.

    Article  PubMed  Google Scholar 

  32. Oshrine B, Bunin N, Li Y, Furth S, Laskin BL. Kidney and bladder outcomes in children with hemorrhagic cystitis and BK virus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(12):1702–7.

    Article  PubMed  Google Scholar 

  33. Laskin BL, Denburg M, Furth S, et al. BK viremia precedes hemorrhagic cystitis in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(8):1175–82.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Zaia J, Baden L, Boeckh MJ, et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):471–82.

    Article  CAS  PubMed  Google Scholar 

  35. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood. 2006;107(5):1800–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Sanz J, Andreu R. Epstein–Barr virus-associated posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation. Curr Opin Oncol. 2014;26(6):677–83.

    Article  CAS  PubMed  Google Scholar 

  37. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Bontant T, Sedlacek P, Balduzzi A, et al. Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT. Bone Marrow Transplant. 2014;49(2):276–9.

    Article  CAS  PubMed  Google Scholar 

  39. Yahav D, Gafter-Gvili A, Muchtar E, et al. Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer. 2009;45(18):3131–48.

    Article  PubMed  Google Scholar 

  40. • Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014; 370(19): 1781–9. Adult phase II RCT demonstrating safety and efficacy of letermovir prophylaxis following HSCT.

  41. • Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013; 369(13): 1227–36. Adult RCT using twice weekly brincidofovir prophylactically post HSCT, showing a reduction in CMV infection and/or viraemia compared with placebo.

  42. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–92.

    Article  CAS  PubMed  Google Scholar 

  43. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403–10.

    Article  CAS  PubMed  Google Scholar 

  44. Miller AN, Glode A, Hogan KR, et al. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17(8):1176–81.

    Article  CAS  PubMed  Google Scholar 

  45. Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2014-2015. Pediatrics. 2014;134:e1503–19.

  46. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. • Blyth E, Clancy L, Simms R, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013; 121(18): 3745–58. Prospective non-randomised trial demonstrating a reduced need for subsequent CMV therapy with CMV specific T-cells compared with controls.

  48. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114(19):4283–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64–76.

    Article  PubMed  Google Scholar 

  51. Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013;21(11):2113–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602.

    PubMed  Google Scholar 

  53. Fisher JP, Bate J, Hambleton S. Preventing varicella in children with malignancies: what is the evidence? Curr Opin Infect Dis. 2011;24(3):203–11.

    Article  PubMed  Google Scholar 

  54. Groll AH, Kurz M, Schneider W, et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses. 1999;42(7–8):431–42.

    Article  CAS  PubMed  Google Scholar 

  55. Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol. 2005;27(3):135–40.

    Article  PubMed  Google Scholar 

  56. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. •• Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014; 61(3): 393–400. Latest evidence based guidelines for fungal prophylaxis in paediatric HSCT and oncology patients (Canadian Group).

  58. •• Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014; 15(8): e327–40. Latest evidence based guidelines for fungal prophylaxis in paediatric HSCT and oncology patients (European Group).

  59. Marr KA, Bow E, Chiller T, et al. Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):483–7.

    Article  CAS  PubMed  Google Scholar 

  60. Blyth CC, Chen SC, Slavin MA, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics. 2009;123(5):1360–8.

    Article  PubMed  Google Scholar 

  61. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121(5):e1286–94.

    Article  PubMed  Google Scholar 

  62. Tragiannidis A, Roilides E, Walsh TJ, Groll AH. Invasive aspergillosis in children with acquired immunodeficiencies. Clin Infect Dis. 2012;54(2):258–67.

    Article  PubMed  Google Scholar 

  63. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood. 1995;86(6):2063–72.

    CAS  PubMed  Google Scholar 

  64. Pagano L, Caira M. The role of primary antifungal prophylaxis in patients with haematological malignancies. Clin Microbiol Infect. 2014;20(Suppl 6):19–26.

    Article  CAS  PubMed  Google Scholar 

  65. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–51.

    Article  CAS  PubMed  Google Scholar 

  66. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–52.

    Article  CAS  PubMed  Google Scholar 

  67. Blyth CC. Antifungal azoles: old and new. Pediatr Infect Dis J. 2011;30(6):506–7.

    Article  PubMed  Google Scholar 

  68. Fasano C, O’Keeffe J, Gibbs D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis. 1994;13(4):351–4.

    Article  CAS  PubMed  Google Scholar 

  69. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25(34):5471–89.

    Article  CAS  PubMed  Google Scholar 

  70. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  71. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.

    Article  CAS  PubMed  Google Scholar 

  72. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.

    Article  CAS  PubMed  Google Scholar 

  73. • Bernardo VA, Cross SJ, Crews KR, et al. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother. 2013; 47(7–8): 976–83. Posaconazole pharmacokinetics study in paediatric and young adult patients suggesting weight-based dosing in children and adolescents. Limited pharmakokinetic data has been available previously.

  74. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51(3):812–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med. 1994;97(6):509–14.

    Article  CAS  PubMed  Google Scholar 

  76. Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol. 2002;71(4):260–7.

    Article  CAS  PubMed  Google Scholar 

  77. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 1993;12(6):577–82.

    CAS  PubMed  Google Scholar 

  78. Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 1999;23(2):163–8.

    Article  CAS  PubMed  Google Scholar 

  79. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46(9):1401–8.

    Article  CAS  PubMed  Google Scholar 

  80. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–16.

    Article  PubMed  Google Scholar 

  81. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50(1):143–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatr Blood Cancer. 2012;59(1):21–6.

    Article  PubMed Central  PubMed  Google Scholar 

  83. Meuwissen JH, Tauber I, Leeuwenberg AD, Beckers PJ, Sieben M. Parasitologic and serologic observations of infection with Pneumocystis in humans. J Infect Dis. 1977;136(1):43–9.

    Article  CAS  PubMed  Google Scholar 

  84. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297(26):1419–26.

    Article  CAS  PubMed  Google Scholar 

  85. •• Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database of Systematic Reviews 2014; 10: CD005590. Recent meta-analysis of available trials of PCP prophylaxis in children and adults demonstrating a clear reduction in mortality and infection compared with placebo.

  86. Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis. 1999;29(6):1467–71.

    Article  CAS  PubMed  Google Scholar 

  87. Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000;6(1):35–43.

    Article  CAS  PubMed  Google Scholar 

  88. Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant. 2012;26(3):E184–90.

    Article  CAS  PubMed  Google Scholar 

  89. Madden RM, Pui CH, Hughes WT, Flynn PM, Leung W. Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer. 2007;109(8):1654–8.

    Article  CAS  PubMed  Google Scholar 

  90. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316(26):1627–32.

    Article  CAS  PubMed  Google Scholar 

  91. • Caselli D, Petris MG, Rondelli R, et al. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr. 2014; 164(2): 389–92. e1. A survey of PCP prophylaxis across 20 centres suggesting single-day/week dosing regimen may suffice for PCP prophylaxis in paediatric patients.

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Princess Margaret Hospital for Children, Roberts Rd, Subiaco, Perth, WA, Australia

    Daniel K. Yeoh & Christopher C. Blyth

  2. Department of Haematology and Oncology, Princess Margaret Hospital for Children, Roberts Rd, Subiaco, Perth, WA, Australia

    Anne L. Ryan

  3. School of Paediatrics and Child Health, University of Western Australia, Roberts Rd, Subiaco, Perth, WA, Australia

    Christopher C. Blyth

  4. PathWest Laboratory Medicine WA, Princess Margaret Hospital for Children, Roberts Rd, Subiaco, Perth, WA, Australia

    Christopher C. Blyth

  5. Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia

    Christopher C. Blyth

Authors
  1. Daniel K. Yeoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne L. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher C. Blyth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher C. Blyth.

Additional information

This article is part of the Topical Collection on Haematology/Oncology.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yeoh, D.K., Ryan, A.L. & Blyth, C.C. Infectious Prophylaxis in Paediatric Oncology and Stem Cell Transplantation. Curr Pediatr Rep 3, 160–169 (2015). https://doi.org/10.1007/s40124-015-0076-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40124-015-0076-x

Keywords

Search

Navigation